About Single Ig IL-1-related receptor
Single Ig IL-1-related receptor (SIGIRR) is a protein
from Homo sapiens identified by UniProt accession
Q6IA17, 410 residues long.
MolForge cross-references it against 0 known binders and
116 disease associations.
Target properties
| Protein name | Single Ig IL-1-related receptor |
| UniProt accession | Q6IA17 |
| Gene | SIGIRR |
| Organism | Homo sapiens |
| Length | 410 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (116)
Diseases linked to this target (Open Targets).
- lymphocyte count · score 0.39
- neurodegenerative disease · score 0.33
- apolipoprotein A 1 measurement · score 0.32
- creatinine measurement · score 0.25
- C-reactive protein measurement · score 0.25
- high density lipoprotein cholesterol measurement · score 0.23
- triglyceride measurement · score 0.16
- neutrophil percentage of leukocytes · score 0.16
- nevus count · score 0.09
- cutaneous melanoma · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q6IA17-F1 | alphafold | PREDICTED | 75.16 | — |
Amino-acid sequence (410 residues)
MPGVCDRAPD FLSPSEDQVL RPALGSSVAL NCTAWVVSGP HCSLPSVQWL KDGLPLGIGG HYSLHEYSWV KANLSEVLVS SVLGVNVTST EVYGAFTCSI QNISFSSFTL QRAGPTSHVA AVLASLLVLL ALLLAALLYV KCRLNVLLWY QDAYGEVEIN DGKLYDAYVS YSDCPEDRKF VNFILKPQLE RRRGYKLFLD DRDLLPRAEP SADLLVNLSR CRRLIVVLSD AFLSRAWCSH SFREGLCRLL ELTRRPIFIT FEGQRRDPAH PALRLLRQHR HLVTLLLWRP GSVTPSSDFW KEVQLALPRK VQYRPVEGDP QTQLQDDKDP MLILRGRVPE GRALDSEVDP DPEGDLGVRG PVFGEPSAPP HTSGVSLGES RSSEVDVSDL GSRNYSARTD FYCLVSKDDM
Explore Single Ig IL-1-related receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets